ArticleInternational journal of clinical oncology2021

Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients.

Takayuki Tokunaga et al.PubMed ↗Publisher ↗

No numbers read from the abstract.